Agilent Technologies, Inc. (NYSE:A) Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC cut its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 68.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,416 shares of the medical research company's stock after selling 18,413 shares during the period. Cresset Asset Management LLC's holdings in Agilent Technologies were worth $1,132,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in A. CKW Financial Group boosted its stake in shares of Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after purchasing an additional 100 shares during the period. Global X Japan Co. Ltd. boosted its stake in shares of Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after purchasing an additional 116 shares during the period. Redwood Park Advisors LLC purchased a new position in shares of Agilent Technologies in the fourth quarter valued at approximately $27,000. Lee Danner & Bass Inc. purchased a new position in shares of Agilent Technologies in the fourth quarter valued at approximately $29,000. Finally, Hanson & Doremus Investment Management lifted its stake in Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after acquiring an additional 105 shares during the last quarter.

Agilent Technologies Stock Down 1.6%

A stock opened at $106.93 on Monday. The company has a fifty day moving average price of $111.53 and a 200 day moving average price of $128.76. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $155.35. The company has a market cap of $30.49 billion, a price-to-earnings ratio of 24.58, a price-to-earnings-growth ratio of 3.01 and a beta of 1.27. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The firm had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Sell-side analysts expect that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st were paid a $0.248 dividend. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.93%. Agilent Technologies's dividend payout ratio is currently 22.76%.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now directly owns 35,737 shares of the company's stock, valued at approximately $4,161,931.02. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the transaction, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This trade represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on A shares. Wells Fargo & Company decreased their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Robert W. Baird decreased their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Barclays decreased their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Jefferies Financial Group decreased their price target on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research note on Monday, April 21st. Finally, TD Cowen lifted their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $143.00.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.